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Abstract
Background: It is known that genetic predisposition to rheumatoid arthritis (RA) is associated with the MHC class II allele
HLA-DR4 and that residues 261–273 of type II collagen (huCollp261) represent an immunodominant T cell epitope restricted
by the DR4 molecule. Despite recent advances in characterization of MHC and T cell receptor (TCR) contacts to this epitope,
the atomic details of TCR/huCollp261/HLA-DR4 ternary complex are not known.
Methodology/Principal Findings: Here we have used computational modeling to get insight into this interaction. A three-
dimensional model of the TCR Vb domain from a DR4
+ patient affected by RA has been derived by homology modeling
techniques. Subsequently, the structure of the TCR Vb domain in complex with huCollp261/HLA-DR4 was obtained from a
docking approach in conjunction with a filtering procedure based on biochemical information. The best complex from the
docking experiments was then refined by 20 ns of molecular dynamics simulation in explicit water. The predicted model is
consistent with available experimental data. Our results indicate that residues 97–101 of CDR3b are critical for recognition of
huCollp261/HLA-DR4 by TCR. We also show that TCR contacts on p/MHC surface affect the conformation of the shared
epitope expressed by DR alleles associated with RA susceptibility.
Conclusions/Significance: This work presents a three-dimensional model for the ternary complex TCR-Vb/collagenII(261–
273)/HLA-DR4 associated with rheumatoid arthritis that can provide insights into the molecular mechanisms of self
reactivity.
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Introduction
Recognition by T cell receptors (TCRs) of antigenic peptides (p)
presented by class I or class II major histocompatibility complex
(MHC) protein is central to cellular immune responses [1,2]. The
molecular events taking place at the TCR/p/MHC interface are also
directly involved in immunomediated diseases. Rheumatoid arthritis
(RA) is an autoimmune disease characterized by a chronic
inflammation of the synovial joints leading to a progressive
destruction of the articular cartilage that progressively invalidates
patients [3]. Genetic predisposition to RA has been significantly
associated with the HLA class II alleles HLA-DRB1 01 and HLA-
DRB1 04 [4,5]. DR b-chain encoded by these RA-related DRB1
genes possess a ‘‘shared epitope’’ formed by conserved amino acids at
positions 67–74 [6]. It has been observed that sequence differences in
this region, especially in residue 71, strongly influence T cell
recognition and immune response [7,8,9] by determining the
selection of peptides presented by the DR molecule [8].
Although the etiology of rheumatoid arthritis remains unknown,
type II collagen is a strong candidate autoantigen. It is the
predominant protein of articular cartilage, and autoimmunity to
type II collagen is commonly detected in patients with RA [10,11].
T cell responses in experimental collagen-dependent RA are
directed towards the immunodominant pathogenic epitope
encompassing residues 261–273 of collagen II [12,13] (here-after
called huCollp261).
Elucidating the mechanism underlying the molecular recogni-
tion of huCollp261/HLA-DR4 by TCR requires structural models
of the complex. Till now, approximately 20 TCR/p/MHC
complex structures have been solved and among these, eight are
TCR/p/MHC of class II structures. Most contacts between TCR
and peptide occur through the CDR3 loops, which exhibit the
greatest degree of variability whereas the preponderance of
generally conserved contacts with the MHC a helices is mediated
through CDR1 and CDR2 [14]. So far, however, no crystal
structure has been published for a TCR in complex with human
type II collagen peptide/MHC assembly.
In our recent study, we used the VB-JB spectratyping (the so
called ‘‘immunoscope’’ technique) to identify T cells specific for
huCollp261 of DR4
+ subjects in the early phases of RA [15]. This
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approximately 3000 groups on the basis of the VB and JB
segments recombined and of the length of the CDR3 region that
varies according to bases additions and subtractions at the V-D-J
joint [16]. In the index DR4
+ RA patient studied thoroughly by
immunoscope [15], we identified and sequenced the CDR3 of a
TCR b-chain belonging to T cells specifically stimulated by
huCollp261 that are present in the blood and spontaneously
enriched in the synovial fluid of inflamed joints. This TCR is
obtained by recombination of VB1 and JB2.6 and has the
following CDR3 region (VB1)CASS DTGS SGAN(BJ2.6). This
sequence is termed here VB1
OE. We also studied a DR4
2DR1
+
RA patient and found one T cell expanding specifically in
response to huCollp261 that used a TCR obtained by recombi-
nation of the same VB1 and JB2.6, having a CDR3 region of the
same length, but displaying a sequence (VB1)CASS GDRS
AGAN(JB2.6). This sequence is termed here VB1
VB. This TCR
recognizes the same peptide but in a conformation different from
the one recognized by VB1
OE since the DR molecule presenting it
is certainly not DR4. The availability of two highly homologues
sequences for TCR b-chains from DR4
+ and DR4
2 patients
affected by RA gave us the opportunity to build a three-
dimensional model of the ternary complex TCR-Vb/hu-
Collp261/HLA-DR4 by computational approaches. The VB1
VB
sequence has been used as a sort of background sample that
provides information about the non-specific contacts that can
emerge when modeling the interaction of a VB1-JB2.6 TCR and
the DR4/huCollp261 complex.
In the work presented here, reasonable structures of TCR Vb
domain and of huCollp261 bound to HLA-DR4 were first
constructed by molecular modeling methods. Subsequently, we
identified an equilibrated reasonable structure of the TCR-Vb/
huCollp261/HLA-DR4 ternary complex using protein-protein
docking and molecular dynamics simulations. On the basis of the
final complex structure and simulation results, we elucidated the
molecular basis underlying the selectivity of the interaction within
this ternary complex.
Methods
Ethics Statement
Informed written consent was obtained from all the patients.
The research is in compliance with the Helsinki Declaration. The
research was approved by the Institutional Ethical Committee of
the Catholic University of the Sacred Heart.
Patients and TCR Vb domain sequencing
Patients OE and VB satisfied the American College of
Rheumatology criteria for RA. Patients were characterized for
the HLA-DR haplotype by PCR-SSO, using the Inno-LiPA HLA-
DRB1 Amp Plus kit (Innogenetics N.V., 9052 Gent, Belgium),
according to manufacturer’s instructions.
In our previous work, we described the clinical characteristics of
patient OE as well as TCR repertoire analysis and sequencing of
the TCR Vb domains of patient OE [15]. In this study we used
the same protocols for TCR repertoire analysis and sequencing of
the TCR Vb domains of patient VB. DNA sequence was
translated into protein sequence through the ExPASy Proteomics
Server.
Homology modeling of TCR Vb domains
Sequences of TCR b-chains for which the three-dimensional
structure was known were selected based upon similarity using
PSI-BLAST (available on the World Wide Web at blast.ncbi.nlm.
nih.gov/Blast). The homology model was based on the structure of
human autoimmune TCR bound to a myelin basic protein self-
peptide and a multiple sclerosis-associated HLA class II allele
(Protein Data Bank (PDB) code: 1zgl) [17]. VB1
VB and VB1
OE
were aligned with the crystallographic TCR Vb domain of 1zgl
using ClustalW (available on the World Wide Web at clustalw.
genome.ad.jp/) and rendered using ESPript program [18]. Based
on ClustalW alignments three-dimensional models of VB1
VB and
VB1
OE were generated by comparative protein modeling with
MODELLER [19] module in Discovery Studio Modeling1.1
(Accelrys Inc.).
Twenty models, optimized by a short simulated annealing
refinement protocol available in MODELLER, were generated for
each Vb domain. The simulated annealing procedure was carried
out in vacuo (dielectric constant =1) considering that in
MODELLER, the effect of solvation, like electrostatics, is assumed
to be encoded in the template structure and thus in the distance
restraints derived from the template. The temperatures used in the
simulated annealing procedure were 150 K, 250 K, 400 K,
1000 K for heating and 800 K, 600 K, 500 K, 400 K, 300 K
for cooling.
The geometrical consistency of the model was evaluated based
on PDF violations provided by MODELLER. The models were
then evaluated using the programs VERIFY3D [20], PRO-
CHECK [21] and by visual inspection using the computer
graphics program Discovery Studio 2.1 (Accelrys Inc.)
Molecular modeling of DR4/huCollp261 complex
Twenty conformations of huCollp261 (AGFKGEQGPKGEP,
position 1, P1 = F) bound to HLA-DR4 were generated using the
simulated annealing protocol of MODELLER and HLA-DR4 in
complex with human collagen peptide 1168–1180 (PDB code:
2seb) as starting structure [22]. The objective function used for
structure generation in MODELLER is referred to as a molecular
PDF (probability density function). This is a combination of all the
feature PDFs used to restrain particular geometric features of the
protein model. Molecular PDF values are collected to Table 1 and
the best-ranked model based on PDF violations (Model 8) was
selected.
The quality of the structures was assessed using VERIFY3D
[20] and PROCHECK [21] (Table 1).
The b105–b112 and b165–b168 sequences, which were not
resolved in 2seb x-ray crystal structure, were built with an ab initio
modeling routine of MODELLER [19].
Protein-protein docking
Docking of all protein pairs was performed with the FTDOCK
program [23]. FTDOCK is based on rigid-body geometric
docking method originally proposed by Katchalski-Katzir et al.
[24]. In this approach the relatively larger protein is held fixed
while the smaller protein translates and rotates on a defined grid
surface so as to establish the best geometric fit. FTDOCK uses fast
Fourier transformation (FFT) grids to rapidly evaluate shape
complementarity. A simple Coulombic model is then used as a
binary filter, leaving only those complexes with attractive
electrostatic interactions. Large positive FTDOCK scores denote
complex formation with good surface complementarity, a score of
zero indicates that the molecules do not interact at all and the
score is negative if the smaller molecule significantly overlaps with
the larger one. In all our calculations FTDOCK was run with
electrostatics on using default parameters. For all protein pairs the
rigid-body docking approach of FTDOCK resulted in 10,000
possible docked complexes which were reduced by a filtering
procedure, based on biochemical knowledge. Interaction energies
Modeling TCR/p-MHC Interaction
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11550were computed using CHARMM [25] as implemented in
DiscoveryStudio (Accelrys Inc.). The NACCESS program [26]
was used to calculate the interface Accessible Surface Area (ASA).
Validation of docking method
The methodology was first tested on the complex of the human
TCR HA1.7 specific for the hemagglutinin antigen peptide (HA)
from influenza A virus bound to class II molecule HLA-DR4 (PDB
code: 1j8h) [27]. The system was digitized onto a 24662466246
grid with the resolution of 0.69 A ˚. The distance constraint applied
required the separation between the following residues and protein
chains to be ,4.5 A ˚: 30D:A 30D:B 50D:A 50D:B (97–98)D:P
where A and B stand for a and b chain of HLA-DR4, respectively,
D stands for b chain of TCR, P stands for HA peptide. This
biological filter was selected based on the hypothesis of the two-
step binding mechanism for T-cell receptor recognition of p/
MHC complex for which the TCR binds p/MHC in a conserved
diagonal orientation that first positions the CDR1 and the CDR2
loops mainly over the HLA-DR4 and then the CDR3 loops over
the peptide [28]. The two-step binding mechanism is consistent
with TCR/p/MHC crystal structures which show that the CDR1
and CDR2 loops primarily contact the MHC, whereas the highly
diverse CDR3 loops mainly interact with the peptide [29].
The first part of the notation (30D:A 30D:B 50D:A 50D:B),
therefore, which refers to the first step of the mechanism, means
that we first isolated the diagonal orientations in which residues
b30 and b50 of CDR1 and CDR2, respectively, are within 4.5 A ˚
distance of any residue of MHC a and b chains. Subsequently,
according to the second part of the notation ((97–98)D:P), related
to the second step of the mechanism, we isolated the complexes for
which residues b97 and b98, at the apex of CDR3, are closer than
4.5 A ˚ to atoms of the antigen peptide.
Analysis of TCR/p/MHC crystal structures clearly indicates
that residues b30 and b50 of CDR1 and CDR2, respectively, and
b97 and b98 of CDR3 make the most frequent contacts for TCRs
to p/MHC [29].
Docking of TCR-VB1
VB and TCR-VB1
OE to huCollp261/
HLA-DR4 complex
The systems were digitized onto a 20662066206 (VB1
VB) and
20262026202 (VB1
OE) grid with the resolution of 0.69 A ˚. The
same filtering procedure of 1j8h complex was applied, which
corresponded to: 32D:A 32D:B 52D:A 52D:B (100–101)D:P
where A, B stand for a and b chain of HLA-DR4, respectively, D
stands for b chain of TCR, P stands for huCollp261.
Molecular dynamics simulations
The best structural model of the ternary complexes TCR-
VB1
OE/huCollp261/HLA-DR4 obtained from docking experi-
ments, i.e. the model with the largest binding energy, largest
interface ASA and that is likely to have biological meaning, was
subjected to aqueous-phase MD simulations using GROMACS
v.3.3.1 and employing the GROMOS96 force field [30]. The
structure was immersed in a triclinic box with periodic boundary
conditions and was solvated with explicit SPC water molecules.
The system was then neutralized by 20 Na
+ counterions that were
added at random positions to the bulk solvent. The dimensions of
the box (9.0 nm69.3 nm 611.4 nm) were set to allow at least
1.2 nm between protein and box faces on each side. The final
system consisted of 5182 protein atoms surrounded by 30000
water molecules. Before running simulation, the system was energy
minimized for 1000 iterations of steepest descents and then
equilibrated for 20 ps, during which the protein atoms were
restrained. All restraints were then removed from the complexes
and the temperature of system was brought to 300 K in a stepwise
manner: 10-ps long MD runs were carried out at 50, 100, 200 and
250 K before the production runs were started at 300 K. The total
length of simulation was 20 ns. Berendsen coupling was employed
to maintain a constant temperature of 300 K with a coupling
constant t of 0.1 ps. van der Waals interactions were modeled
using 6–12 Lennard-Jones potentials with a 1.4 nm cutoff. Long-
range electrostatic interactions were calculated using Particle
Mesh Ewald method, with a cutoff for the real space term of
1.2 nm. Covalent bonds were constrained using LINCS algorithm.
The time step employed was 2 fs and the coordinates were saved
every 5 ps for analysis of MD trajectories which was carried out
using the standard GROMACS tools g_rms, g_rmsf and g_hbond.
In the use of g_hbond, a cutoff radius of 0.35 nm between donor
and acceptor and a cutoff angle of 30u as geometric criteria were
employed for the existence of a hydrogen bond.
This same MD protocol was applied to all VB1
OE models
emerging from the docking filtering procedure in order to
calculate the interface ASA at the end of the MD run.
Computational alanine scanning
Residues important for the stabilization of the complex were
identified using Baker’s alanine scanning procedure [31,32] and
the Robetta web server (http://www.robetta.org). This approach
calculates van der Waals’ and electrostatic contributions to the free
energy of binding. Positive values of DDG means that the alanine
mutation is predicted to destabilize the complex and negative
values indicate a stabilizing effect. Binding energy ‘‘hot spots’’ are
defined for residues at the subunit-subunit interface, whose Ala
Table 1. Molecular PDF and protein structure analysis for the
twenty models of DR4/huCollp261.
Ramachandran plot quality (%)
Model Molecular PDF Core Allowed General Disallowed
Model 8 2189.39 92.2 6.6 1.2 0.0
Model 11 2209.43 92.5 6.6 0.9 0.0
Model 12 2263.19 93.1 5.7 1.2 0.0
Model 15 2278.74 91.9 6.9 1.2 0.0
Model 10 2283.98 92.2 6.9 0.6 0.3
Model 4 2287.99 91.6 6.9 1.5 0.0
Model 16 2329.97 93.1 5.4 1.5 0.0
Model 20 2352.77 92.5 6.6 0.9 0.0
Model 9 2356.94 92.2 6.6 1.2 0.0
Model 3 2359.49 94.0 5.4 0.6 0.0
Model 5 2373.85 91.6 6.6 1.5 0.3
Model 13 2388.94 92.2 6.9 0.9 0.0
Model 2 2397.23 91.0 7.2 1.8 0.0
Model 19 2403.73 92.5 6.0 1.2 0.3
Model 7 2409.73 92.8 6.6 0.3 0.3
Model 18 2435.51 91.9 6.6 1.5 0.0
Model 17 2529.67 91.6 6.9 1.5 0.0
Model 14 2540.33 92.5 6.3 1.2 0.0
Model 6 3074.24 92.2 6.9 0.9 0.0
Model 1 3235.73 91.9 6.9 0.9 0.3
doi:10.1371/journal.pone.0011550.t001
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mol.
Results and Discussion
Choice of TCR b-chains
The expansion of T cells specific for huCollp261 in DR4
+
subjects was studied by ‘‘immunoscope’’, in the peripheral blood
mononuclear cells (PBMC), as previously reported for the only
patient OE [15]. T cells carrying a rearrangement of VB1 and
JB2.6 of 134b length were particularly interesting. This TCR is in
fact enriched spontaneously in the inflamed synovia. In addition,
its usage appeared specifically linked to DR4 haplotype and RA
development. In fact, p139-specific cells using a rearrangement of
this type were present in 4/6 DR4
+ patients during acute
presentation of the disease (3 samples) and remission (2 samples).
Meanwhile, we did not find cells carrying this rearrangement in
any of 5 DR4
+ healthy donors.
In a separate set of experiments, not previously reported, we
tested 4 more subjects, 2 DR1
+ DR4
2 RA patients, 1 DR1
2
DR4
2 RA patient and 1 patient suffering from acute arthritis of
other origin. Out of this latter group of patients, one DR4
2DR1
+
RA patient (patient VB) displayed the usage of a VB1-JB2.6 of
134b length in response to stimulation with huCollp261. Since T
cells from this patient recognized huCollp261 most likely in the
contest of DR1, we sequenced and modeled the VB1-JB2.6 134b
TCR b-chain from this patient to obtain a control for the
specificity of the modeled interaction between the TCR b-chain
obtained from DR4
+ patient OE, huCollp261 and the DR4
molecule itself.
Modeling of TCR Vb domains and of huCollp261/HLA-
DR4 complex
Homology models of VB1
VB and VB1
OE domains were
constructed with the program MODELLER which implements
an automated approach to comparative protein structure model-
ing by satisfaction of spatial restraints. The program automatically
generates a set of restraints that includes the CHARMM
forcefield, statistical preferences mined from PDB, and distance
and dihedral restraints extracted from aligned templates, than
generates a set of models which are consistent with all restraints.
To find template structures, a specific BLAST sequence search of
the Protein Data Bank (PDB) using default parameters was
performed. The convergence matrix used to search the PDB
produced significant alignments with the autoimmune TCR
bound to a myelin basic protein self-peptide and a multiple
sclerosis-associated HLA class II molecule (PDB code: 1zgl;
identity 62%, similarity 75% with VB1
VB; identity 63%, similarity
76% with VB1
OE), the TCR Vb5.1 in complex with staphylococ-
cal enterotoxin K (SEK) (PDB code: 2nts; identity 62%, similarity
75% with VB1
VB; identity 63%, similarity 76% with VB1
OE), the
TCR in complex with an anti-TCR Fab fragment derived from a
mitogenic antibody (PDB code: 1nfd; identity 58%, similarity 72%
with VB1
VB; identity 58%, similarity 72% with VB1
OE). The 1zgl
complex in which human TCR is bound to HLA-DR2 protein
appeared the appropriate template for comparative modeling of
VB1
VB and VB1
OE b chains. The alignment of VB1
VB and
VB1
OE domains with 1zgl generated by ClustalW is reported in
Fig. 1A. The twenty different models generated for each Vb
domain by MODELLER were carefully analyzed for energy value
and probability density function (PDF) violations. Among the first
three original models, which were quite similar with respect to
violations and energy values, the model possessing the least root
mean square deviation (RMSD) value with the backbone atoms of
1zgl (0.23 A ˚ for VB1
VB and 0.26 A ˚ for VB1
OE), was selected for
further study. The goodness of the folding was assessed by
VERIFY-3D, which evaluates the compatibility of a given residue
in a certain three-dimensional environment. As shown in Fig. 1B,
the three/one-dimensional scores of our models are always
positive and are similar to those obtained with the template
structure of 1zgl. PROCHECK analysis indicates that the quality
of the Ramachandran plots (97.9% of the residues in the allowed
regions) were equivalent to those of the template structure. The
superimposition of the modeled TCR Vb structures is reported in
Fig. 1C. CDR3 Ser100 of both VB1
VB and VB1
OE is positioned at
the apex and appears most accessible for interaction with peptide/
HLA-DR4 complex. The flanking residues (Arg99 and Ala101 in
VB1
VB, Gly99 and Ser101 in VB1
OE) may play important roles in
the packing of the CDR3 loop structures.
Modeling of huCollp261 peptide (AGFKGEQGPKGEP, posi-
tion 1, P1 = F) bound to HLA-DR4 was performed using the
simulated annealing protocol of MODELLER and the crystallo-
graphic complex between human collagen peptide (CII) 1168–
1180 and HLA-DR4 as starting structure. It is worth noticing that
the automatically generated three-dimensional model (Fig. 2)
displays the same structural features proposed for the DR4
recognition of huCollp61 by Dessen et al. [22] simply on the basis
of the analysis of the MHC class II structures determined to date.
In fact, observing that the peptides in complexes with human and
murine MHC class II molecules have remarkably similar
conformations, with P1, P4, P6, P7 and P9 partially buried in
pockets and P-2, P-1, P2, P3, P5, P8, P10 and P11 substantially
exposed to solvents, Dessen et al. hypothesize how the CII(261–
273) peptide could be aligned and modeled from the DR4/
CII(1168–1180) structure. In agreement with Dessen et al.
working hypothesis, in our computationally-generated model
Phe263 (P1) of huCollp261 is bound in the large nonpolar pocket
1 which was occupied by Met in the CII(1168–1180)/DR4
complex; Glu266 (P4) is hydrogen bonded to Lys71b as does P4
Asp in CII(1168–1180); Pro269 (P7) fits in the shallow pocket 7
(Fig. 2). As expected, Gln267 (P5) and Lys270 (P8), extend
prominently into solvent where can be contacted by TCR (Fig. 2).
In addition, as hypothesized [22], CII(1168–1180) main-chain
hydrogen bonds to DR4 are maintained in the model.
Docking validation
To validate the docking method, we first applied our technique
to the rebuilding of a known TCR/p/MHCII crystallographic
structure. The complex of TCR Vb domain specific for the
hemagglutinin antigen peptide (HA) with HLA-DR4 (PDB code:
1j8h) was selected for this purpose. FTDOCK was used to scan the
relative orientations of the molecular complex in a systematic way,
and produced 10,000 docking orientations. For the 10,000 docked
models, we calculated the root mean square deviation (RMSD) of
Ca atoms of each model structure from the native complex
structure (1j8h). We observed that there are only two complexes
with RMSD ,4.5 A ˚ (2.43 A ˚ and 4.27 A ˚) and 17 complexes with
4.5 A ˚ , RMSD ,8A ˚. The rest have very high RMSD.
The 10,000 structures werethen filtered by the distance constraints
using available biological information. We first took into account the
the two-step binding mechanism [28] for TCR recognition as a
means of filtering the docking results. In this model, initial TCR-
MHC interactions, aided by minor contributions from TCR contacts
with the peptide, guide the TCR to its ligand. This is followed by a
final folding of the CDR3 loops of the TCR over the peptide [28].
Analysis of TCR/p/MHC crystallographic structures [29], which is
consistent with the two-step binding mechanism, indicated the
constraints for filtering procedure. We initially eliminated the models
Modeling TCR/p-MHC Interaction
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respectively, were positioned away (.4.5 A ˚)f r o mM H Ca and b
chains; then, among the remaining predictions, only those that had a
distance less than 4.5 A ˚ between Leub97 and Prob98 of CDR3 and
any residue of the HA peptide, were kept for further analyses. The
eight remaining models were examined using the molecular graphics
display program DiscoveryStudio (Accelrys Inc.) and a further
biological filter was applied following the structural analysis of Deng
and Mariuzza [33] which points out how the three CDR loops of Vb
contact the central and C-terminal portion of peptide. Therefore,
complexes for which the CDR3b does not focus on the central
portion of the MHC-bound peptide (P5-P6) were eliminated [33].
This left four models which were energy-minimized. Among these,
the complex possessing the largest interaction energy between TCR
Vb and p/MHC and the greatest buried surface area is the same
model structure exhibiting the lowest RMSD among the original
10,000 docked models (Ca RMSD =2.43 A ˚). We were thus
confident that FTDOCK can generate TCR/p/MHC model
complexes close to native structures and this procedure was chosen
to study the interaction of VB1
VB and VB1
OE TCR domains with
huCollp261/HLA-DR4 complex.
Docking of VB1
VB and VB1
OE domains with huCollp261/
HLA-DR4 complex
The same docking protocol and filtering procedure successfully
used for method validation was then employed to investigate the
docking of VB1
VB and VB1
OE domains with huCollp261/HLA-
DR4 complex. The selection of residues for filtering constraints
based on the two-step binding mechanism for TCR recognition
[28] and on the analysis of TCR/p/MHC crystal structures [29].
Figure 1. Modeling of TCR-VB1
VB and TCR-VB1
OE domains. A) Sequence alignment of VB1
VB and VB1
OE with 1zgl Vb domain. Alignments
were performed with ClustalW algorithm and ESPript software. Identical and similar amino acids are in dark and white boxes, respectively. The
secondary structural elements are shown aligned to their respective sequences. Numbering of amino acids begins with the first amino acid residue of
sequenced VB1
VB and VB1
OE; B) Residue-based quality assessment results obtained by the Verify3D program using the coordinates of 1zgl crystal
structure (black) and the coordinates of the three-dimensional models of VB1
VB and VB1
OE (continuous grey and dashed grey, respectively). X axis:
amino acid numbering of VB1
VB and VB1
OE starting from the first sequenced residue. Y axis: average three/one-dimensional scores for residues in a
21-residue sliding window; C) Ca trace of VB1
VB (dark blue) and VB1
OE (light blue) model structures superimposed onto the Ca trace of template 1zgl
Vb domain (red). Ser100, at the apex of CDR3 loop of VB1
VB and VB1
OE, is shown in ball and stick representation.
doi:10.1371/journal.pone.0011550.g001
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FTDOCK to a manageable number we first requested Leub32
and Tyrb52 (corresponding to TCR HA1.7 Asnb30 and Aspb50,
respectively) to be positioned at a distance less than 4.5 A ˚ from
MHC a and b chains. Then, according to the second step of the
mechanism, we included only orientations where the peptide was
within 4.5 A ˚ distance from VB1
VB Ser100 and Ala101 and from
VB1
OE Ser100 and Ser101 (corresponding to TCR HA1.7
Leub97 and Prob98, respectively). In doing so, seven complexes
remained for both VB1
VB and VB1
OE. Interaction energies and
interface Accessible Surface Area (ASA) for the selected minimized
complexes are reported in Table 2. In the case of VB1
VB, only
three candidate complexes (namely models #17, #21 and #36 in
FTDOCK ranking) show the Vb domain located over the central
and C-terminal portions of the peptide. Analogously, of the seven
candidate conformations for VB1
OE complex, only three (namely
model #8, model #33 and model #37 in FTDOCK ranking)
display the Vb domain poised above the C-terminal half of the
peptide. Considering that a higher interface ASA is an indication
of a higher shape complementary [26] between the molecules, the
models with the largest binding energy and interface ASA were
chosen as the most reasonable orientation. From the analysis of
Table 2, model #36 in FTDOCK ranking was the most
reasonable model for VB1
VB and model #33 was the most
reasonable for VB1
OE. Visual inspection of candidate conforma-
tions reported in Table 2 also showed that the binding
conformations #36 (VB1
VB) and #8 (VB1
OE) are very similar
with overall RMSD of 1.36 A ˚ when the Ca atoms are optimally
aligned. The three models emerging from the docking studies,
namely #36
VB, #8
OE and #33
OE are reported in Figure 3. If we
look at the regions of the proteins involved in the interaction, we
see an important difference among the models. CDR3b of model
#36
VB and #8
OE focus on the peptide C-terminus, whereas in
model #33
OE CDR3b is positioned above P5-P6 of peptide as
observed in binding topologies of autoimmune complexes [33]. As
stated in the introduction, VB1
VB recognizes huCollp261 bound to
an HLA molecule different from DR4. Model #36
VB, therefore,
Figure 2. Model of huCollp261 peptide in the HLA-DR4 binding
cleft. The computationally generated model closely resembles the
hypothetical model suggested by Dessen et al. (22) for the DR4
recognition of huCollp261. Phe263 fits into the P1 pocket and Glu266
(P4) hydrogen bonds to Lys71b. The MHC peptide-binding groove is
represented with Connolly solid surface, whereas the ligand peptide is
shown in stick representation.
doi:10.1371/journal.pone.0011550.g002
Table 2. Interaction energy and interface Accessible Surface
Area (ASA) in the minimized complexes emerging from
docking calculations.
BV1
VB BV1
OE
FTDOCK
score
Eint
(kcal/mol) ASA (A ˚ 2)
FTDOCK
score
Eint
(kcal/mol) ASA (A ˚ 2)
8 246.6 1176.5 8 245.3 1181.1
17 253.8 1224.6 13 246.7 851.4
21 256.6 1298.6 14 254.5 1247.9
33 234.6 1201.3 29 243.5 977.0
36 262.5 1370.5 33 263.7 1384.8
52 241.5 1065.3 34 256.0 1198.1
56 250.4 1235.2 37 254.4 1077.0
doi:10.1371/journal.pone.0011550.t002
Figure 3. Molecular docking results. Structural comparison of overall structures of TCR-Vb/huCollp261/HLA-DR4 complex models #36 (VB1
VB),
#8 (VB1
OE) and #33 (VB1
OE) emerging from the docking study. Color coding is as follows: magenta, TCR-Vb domain; blue, HLA-DR4; green, peptide.
doi:10.1371/journal.pone.0011550.g003
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that any TCR b-chain, generated by recombination of VB1 and
BJ2.6 of the same length, engages with the huCollp261/HLA-
DR4 complex. Since model #8
OE is very similar to this non-
specific interaction, we selected model #33
OE as the complex
structure for TCR-VB1
OE/huCollp261/HLA-DR4 complex most
likely provided of biological meaning.
Molecular dynamics simulation
The model emerging from the docking was further investigated
by MD simulation. Evaluation of structural drift is provided by
analysis of the Ca atom RMSDs from the initial structures as a
function of time. The RMSDs of the VB1
OE TCR and of the
huCollp261/HLA-DR4 complex through the 20 ns trajectory
were computed with respect to their corresponding initial
structures. The Ca RMSD values fluctuated for the last 5 ns of
the MD run around values of 3.960.1 and 4.860.2 A ˚ for VB1
OE
TCR and huCollp261/HLA-DR4, respectively (Fig. 4). The
moderately large RMSD of the bound-MHC and, to a lesser
extent, of the bound TCR Vb domain indicates the existence of
conformations that are somewhat different from the starting
structure. A closer inspection of the RMSD for the HLA-DR4
molecule indicates that its variation is mainly due to the
contribution of the several loops in the b2 domain. Analysis of
RMSD for the TCR’s CDRs (Fig. 4, inset) indicates that CDR1
and CDR2, which are positioned almost exclusively over the DR4
helix a1, show high stability reaching a plateau of 0.7 A ˚ and 1.1 A ˚
already after 5 ns. The CDR3 shows a higher deviation (Ca
RMSD values fluctuating around values of 2.460.2 A ˚ in the last
5 ns) indicating that it significantly contributes to the overall
deviation of the TCR b-chain. The RMSDs of the CDRs
correspond to a structural feature of TCR/p/MHC complexes in
which the CDR1 and CDR2 loops are significantly more rigid
than CDR3 loop and show little or no rearrangement upon
binding to the p/MHC complex. In contrast, the CDR3 loop
appears highly flexible and mobile and undergoes substantial
repositioning upon binding the p/MHC complex. Such a behavior
of CDRs is consistent with the reported observation that CDR
loops of the TCR display different conformations in the free and
bound states [34].
Interactions at the protein surface
The average structure over the last 5 ns of simulation was used
to analyze the interactions at the protein surface. The interface
Figure 4. Ca- RMSDs versus time. The time evolution of the RMSD values for huCollp261/HLA-DR4 complex (grey line) and VB1
OE TCR (black line).
Inset shows individuals CDR loops: CDR1 (black line), CDR2 (light grey) and CDR3 (dark grey) computed through the 20 ns MD simulation of VB1
OE
TCR/huCollp261/HLA-DR4 ternary complex.
doi:10.1371/journal.pone.0011550.g004
Table 3. Interaction energy and interface Accessible Surface
Area (ASA) for the VB1
OE/huCollp261/HLA-DR4 complexes
averaged over the MD simulation runs.
FTDOCK score Eint (kcal/mol) ASA (A ˚ 2)
8 2114.1 1645.4
13 267.4 1104.9
14 2108.7 1340.2
29 290.3 1517.2
33 2126.8 1686.5
34 293.4 1483.6
37 266.4 964.5
doi:10.1371/journal.pone.0011550.t003
Table 4. van der Waals contacts
{ between VB1
OE and
huCollp261/HLA-DR4.
VB1
OE HLA-DR4 huCollp261
Ser29 Ala61a, Ala64a, Val65a, Ala68a Pro269
Gly30 Ala61a, Val65a
Leu32 Gln57a, Ala61a
Tyr52 Gln57a, Leu60a
Arg57 Gln57a
Thr98 Gln57a, Gly58a, Ala61a
Gly99 Gln267
Ser100 Gln70b Gln267, Gly268, Pro269
Ser101 Leu67b, Gln70b, Lys71b Glu266, Gln267, Gly268, Pro269
Gly102 Leu67b, Gln70b Pro273
Ala103 Gln70b Pro269, Pro273
Asn104 Asp66b
{van der Waals contacts are #4.0 A ˚.
doi:10.1371/journal.pone.0011550.t004
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that the molecular dynamics run induced a significant improve-
ment in the surface matching. All the VB1
OE models emerging
from the docking (Table 2) were further investigated by MD
simulations to the aim of better evaluating the enhancement of
interface ASA in the selected model #33
OE. The interaction
energy and interface ASA for the seven VB1
OE/huCollp261/
HLA-DR4 complexes averaged over the MD simulation runs are
reported in Table 3. By comparing Tables 2 and 3, we realize that
the ASA value resulted essentially increased in models #8, #13,
#29, #33 and #34, while a less pronounced increase in the ASA
is observed for model #14; a decrease being instead registered for
model #37. Notably, the selected model #33 proved to be the
model with the largest binding energy and interface ASA also at
the end of the MD simulations, thus confirming the validity of the
model selection.
Interactions between TCR and huCollp261/DR4 complex are
mainly restricted to van der Waals contacts, with limited
juxtaposition of hydrophobic surfaces (Table 4). Of note, several
TCR Vb residues make contacts to HLA-DR4 Gln57a, Ala61a
and Gln70b, which stand out as MHC class II conserved contact
residues from the analysis of TCR/p/MHC crystallographic
complexes [29].
Identity of residues 67–74 of MHCII b-chain in DR4 and DR1
(‘‘shared epitope’’ region) has been correlated with increased risk
for RA [35]. In the predicted model we observe that some residues
of the CDR3 loop 97–101 of VB1
OE (DTGSS) form van der
Waals contacts with this ‘‘shared epitope’’ region. As found for
recognition of a myelin basic protein self-peptide by TCR 3A6
Table 5. Intermolecular hydrogen bonds between VB1
OE and
huCollp261/HLA-DR4.
VB1
OE huCollp261 HLA-DR4 Frequency (%)
{
Tyr52 (OH) Gln57a (NE2) 52.24
Arg57 (NH2) Gln57a (NE2) 17.22
Arg57 (NH1) Gln57a (NE2) 20.74
Ser100 (O) Gln70b (NE2) 52.24
Ser101 (OG) Gln70b (O) 17.22
Ser101 (OG) Glu266 (OE1) 20.74
Ser101 (N) Gln267 (O) 52.36
Gly102 (N) Gln70b (OE1) 81.62
{Interactions were statistically monitored throughout the MD trajectory for a
total of 5000 conformations.
doi:10.1371/journal.pone.0011550.t005
Figure 5. Positioning of the TCR VB1
OE domain over the huCollp261/HLA-DR4 complex. A) Overall three-dimensional structure of TCR-
VB1
OE/huCollp261/HLA-DR4 ternary complex generated using molecular dynamics simulations. The backbone structure of VB1
OE (magenta) and HLA-
DR4 (green) are displayed in solid ribbon representation; huCollp261 (yellow) is shown in tube representation. HLA-DR4 is represented with Connolly
transparent solid surface; (B) Zoom view of the peptide binding cleft showing the hydrogen-bonding interactions involving CDR3b; (C) Zoom view of
the binding surface showing TCRb residues important for the stabilization of the complex. Atoms are shown in ball and stick representation and
colored by atom type with the exception of C atoms, colored by subunit.
doi:10.1371/journal.pone.0011550.g005
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TCR Vb domain and the huCollp261 peptide (Table 5), a feature
that likely contributes to low affinity binding and the observed
crossreactivity in autoimmune TCRs [36,37].
Our MD simulation showed that peptide contacts are made
primarily through the CDR3 loop (Table 4, Table 5) which
overlays the central region of the peptide-binding groove (Fig. 5A).
The side chain of peptide Glu266 (P4) is the first CDR3-contact
residue and forms a hydrogen bond with Ser101 OG atom
(Fig. 5B). At various points during the molecular dynamics run,
Ser101 OG atom alternately forms hydrogen bonds with Glu266
OE1 atom and the carbonyl oxygen atom of DR4 Gln70b
(Fig. 5B). Due to the binding of TCR Ser101b to Glu266, Lys71b
of MHC ‘‘shared epitope’’ moves away from Glu266 causing a
separation of 8.8 A ˚ between the side chains of Lys71 and Glu266,
a distance that appears to disfavor a direct contact. Thus, the
Lys71b-Glu266 interaction, suggested by Dessen [22] and by our
modeling (Fig. 2) is significantly affected by TCR binding. The
second CDR3-contact residue of huCollp261 is Gln267 (P5) whose
backbone oxygen atom is hydrogen bonded to Ser101 N atom
(Fig. 5B). Gly268 (P6), Pro269 (P7) and Pro273 (P11) provide
much weaker interactions to the modeled TCR, with Pro269 and
Pro273 loosely interacting with the hydrophobic Ala103 (Table 4).
We had the opportunity to test the hypothesis that Gln267 may
play a relevant role in the recognition of huCollp261 by the TCR
under study, by stimulating in parallel PBMC from patient OE
with a peptide encompassing a subdominant epitope of the same
protein, namely peptide huCollp289–303 (sequence GKRGAR-
GEOGGVGPI, where O is hydroxyproline, Hyp). We showed
that 25% of huCollp261-specific T cells recognize also an epitope
contained in peptide huCollp289–303 [15]. In Figure 6, panel A,
the sequence alignment between huCollp261 and huCollp289–
303 is shown. A functional study [38] identified the ‘‘core’’ epitope
recognized by T cells within peptide 259–273 of human collagen
II in the region encompassing residues 263–268. We can observe
that there are three amino acid residues that are conserved
between huCollp261 and huCollp289–303 within this area, and
that Phe263 of huCollp261 (the most functionally relevant residue
for binding to HLA-DR4 according to the same study [38]) is
aligned with Ala293 of huCollp289–303. TCR of T cells cross-
recognizing huCollp261 and huCollp289–303 will thus possibly
contact conserved residues (i.e. Gly265/295, Glu266/296,
Gly268/298) all of which are indicated by the above-mentioned
study as residues involved in the contact with the TCR. On the
contrary, TCRs of T cells selectively recognizing huCollp261 may
contact residues that are different between the two peptides,
namely Lys264 (replaced by Arg294 in huCollp289-263), whose
functional role however appears more relevant in the binding to
DR4 than in contacting the TCR [38], and Gln267 (replaced by
Hyp297 in huCollp289-263) that is indicated as a main TCR
contacting residue in Ref. [38] in agreement with our modeling
results.
If the TCR studied here (VB1
OE) needs Gln267 for recognition
of huCollp261, as suggested by our model, peptide huCollp289–
303 will fail to stimulate and expand T cells carrying this receptor.
This is actually the case.
We cultured PBMC from patient OE in the presence of
huCollp261 or huCollp289–303, following the protocol described
[15]. Results are shown in panel B of Figure 6, where arrows
indicate the peaks corresponding to the product of the VB1
OE
chain in the immunoscope spectra. T cells carrying the VB1
OE
chain proliferate in response to huCollp261, and expansion of the
corresponding peak (indicated by the arrow) can be observed, as
expected. On the contrary, no proliferation is observed when the
same cells are stimulated with huCollp289–303. These experi-
mental findings are in line with the results of the computational
modeling proposed.
The role of individual amino acids in stabilizing the complex was
inspected by computational alanine scanning [31]. Residues with
DDG.1 kcal/mol are called ‘‘hotspots’’ (Fig. 7) and are listed in
Table 6. Recent computational alanine scanning studies [39] have
shown that location of the ‘‘hotspots’’ may vary among the various
TCR/p/MHC structures. Remarkably, two ‘‘hotspots’’ on TCR
VB1
OE (Leu32 in CDR1 and Tyr52 in CDR2, see Table 6) interact
with DR4a Gln57 and Ala61 (Table 4) which form conserved
contacts with TCR Vb domain [29]. This finding is in close
agreement with the alanine scanning analyses of TCR HA1.7 bound
to HA/HLA-DR4 and to HA/HLA-DR1 (PDB codes: 1j8h and
1fyt, respectively) [39]. Also computational mutation of CDR3 Asp97
hasunfavorableeffectsonthestabilityofthecomplex(Table6).Inthe
dynamically equilibrated model, Asp97 forms a salt bridge with
Arg28 of CDR1 that may be important for maintaining a correctly
orientedloopstructure(Fig.5C).WealsofindthatDR4aGln57Ala is
able to cause destabilization at the interface (Table 6, Fig. 5C) and
this result is consistent with the above-mentioned structural role of
Gln57a. Alanine scanning results also indicate DR4 Gln70b as a
residue whose mutation dramatically affects TCR/p/MHC com-
plex. The network of hydrogen bonds established by Gln70b with
Ser100, Ser101 and Gly102 of the TCR Vb domain is shown in
Fig. 5B. Taken together, these findings lead to the suggestion that the
‘‘shared epitope’’ region plays an essential role in influencing the
Figure 6. T cells carrying the BV1-BJ2.6 TCR b chain do not
expand in response to stimulation with peptide huCollp289–
303. A) Sequence alignment of peptide huCollp261 with huCollp289–
303 performed with ClustalW algorithm and ESPript software. Identical
and similar amino acids are in dark and white boxes, respectively. B)
BV1-BJ2.6 spectra obtained from peripheral blood mononuclear cells
(PBMC) of patient OE stimulated in vitro in the absence of added
antigen (background) or in the presence of 20 mg/ml of peptides
huCollp261 or huCollp289–303. PBMC were obtained from patient OE
during a clinical relapse of disease. They were cultured and cDNA was
obtained. BV-BJ spectratyping for rearrangements of BV1 and BJ2.6 was
performed as described [15]. The spectra report the distribution of each
TCR bCDR3 as a function of its length, where peaks are separated by a
3-base, i.e. one amino acid, difference. The fluorescence of each peak is
a function of the amount of CDR3 of each length. Arrows indicate the
134b peak corresponding to the TCR b-chain under study.
doi:10.1371/journal.pone.0011550.g006
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between TCR and p/MHC complex influences polarization of T
cells, since a strong stimulation leads to acquisition of the pathogenic
Th1 phenotype [40,41]. Thus the direct engagement of the ‘‘shared
epitope’’ by the TCR would contribute to differentiation of T cell
specific for huCollp261 towards a pathogenic phenotype and
promote the development of RA.
Conclusions
The molecular mechanism of collagenII(261–273)/HLA-DR4
recognition by a TCR Vb domain characteristic of a DR4
+ patient
affected by rheumatoid arthritis was investigated using molecular
modeling, protein-protein docking, and molecular dynamics
simulations. It is clear that the possibility of controlling the
clonotypic expansion strictly derives from the knowledge of the
three-dimensional structure of the complex of TCR with the
putative antigen. It is also true that post-transcriptional modifica-
tions of collagen can occur that modify the peptide bound to the
DR4 molecule. Yet the putative natural antigen unmodified by
posttranslational events likely represents the very early initial
trigger of the loss of tolerance occurring under genetic control in
RA, as observed in the collagen type II induced model of arthritis,
possibly along with the posttranslationally modified antigen [42].
Herein, the proposed model finds a correspondence with a large
body of existing experimental data and allows the identification of
key residues involved in complex stability and specificity. As
expected, key residues belong to the region 97–101 of Vb that
distinguishes the TCR of the DR4
+ patient from that of a DR4
2
patient. Furthermore, the simulations presented here suggest that
the ‘‘shared epitope’’, common to the RA-predisposing alleles
HLA-DR4 and HLA-DR1, directly contributes to the engagement
of the TCR itself.
Nowadays, PCR based methods can produce large numbers of
sequences of candidate antigen-specific TCR, specially for the b-
chain.
The molecular modeling method we describe will prove useful
to examine e. g. the variability of the recognition for the same p/
MHC complex by different TCRs.
Although the presented strategy should be validated by
comparison with mutagenesis experiments involving variations in
either peptide or the TCR-Vb molecule, knowledge of the
interactions and key binding residues at the interface between
TCR and p/MHC complexes, obtained by pooling information
from several of these models, will produce a detailed map of the
Figure 7. Hotspots predictions in the TCR VB1
OE -huCollp261/HLA-DR4 interface. Residues predicted to be hotspots (DDG.1.0 kcal/mol)
are shown in red, the huCollp261 peptide in green and the TCR is represented as a yellow ribbon. A) Unbound huCollp261/HLA-DR4 surface; B)
Unbound TCR-VB1
OE surface; C) TCR-VB1
OE/huCollp261/HLA-DR4 complex.
doi:10.1371/journal.pone.0011550.g007
Table 6. Computational alanine scanning-based free energies
for the TCR-VB1
OE/huCollp261/HLA-DR4 complex.
Mutation Protein DDGbind (kcal/mol)
Arg28Ala TCR CDR1b 3.92
Leu32Ala TCR CDR1b 1.33
Tyr52Ala TCR CDR2b 1.61
Asn53Ala TCR CDR2b 2.16
Arg57Ala TCR CDR2b 1.18
Asp97Ala TCR CDR3b 2.11
Glu266Ala huCollp261 1.55
Gln57Ala DR4a 1.96
Lys67Ala DR4a 1.50
Gln70Ala DR4b 2.14
doi:10.1371/journal.pone.0011550.t006
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self- and allo-recognition.
This represents the basis to envision any future strategy to
develop tools capable of damping the autoreactivity or to switch-
off the autoreactive signal occurring from the interaction.
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